Phase I study of the heparanase inhibitor roneparstat: an innovative approach for ultiple myeloma therapy
Authors:
- 26 April 2018
- journal article
- letter
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 103 (10) , e469-e472
Abstract
The role that the bone marrow microenvironment plays in differentiation, migration, proliferation, survival and drug resistance of malignant plasma cells has attracted significant attention in the attempt to identify new druggable targets in multiple myeloma (MM).[1][1] Heparanase is an endo-β-d-Keywords
This publication has 13 references indexed in Scilit:
- Heparanase: From basic research to therapeutic applications in cancer and inflammationDrug Resistance Updates, 2016
- Heparanase regulation of cancer, autophagy and inflammation: new mechanisms and targets for therapyThe FEBS Journal, 2016
- Chemotherapy induces expression and release of heparanase leading to changes associated with an aggressive tumor phenotypeMatrix Biology, 2016
- Kinetic analysis and molecular modeling of the inhibition mechanism of roneparstat (SST0001) on human heparanaseGlycobiology, 2016
- Targeting heparanase overcomes chemoresistance and diminishes relapse in myelomaOncotarget, 2015
- Heparanase as a Target in Cancer TherapyCurrent Cancer Drug Targets, 2014
- Heparanase Stimulation of Protease Expression Implicates It as a Master Regulator of the Aggressive Tumor Phenotype in MyelomaJournal of Biological Chemistry, 2008
- Heparanase Enhances Syndecan-1 SheddingJournal of Biological Chemistry, 2007
- High heparanase activity in multiple myeloma is associated with elevated microvessel density.2003
- Soluble syndecan-1 promotes growth of myeloma tumors in vivoBlood, 2002